Dyne Therapeutics, Inc.
DYN- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001818794
In the last 90 days, Dyne Therapeutics, Inc. insiders filed 0 open-market purchases and 10 sales; 245 institutions reported holding it in 13F filings for Q2 2026, worth $4.23B in total; no superinvestor holds it.
Holders of 5% or more of DYN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Dyne Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| T. Rowe Price Investment Management, Inc. | 13G/A | 16.20%26.6M shares | +5.50 ppfrom 10.70% | Jan 8, 20262 filings | Mar 6, 2026 | SEC |
| Janus Henderson Group PLC | 13G/A | 8.50%13.9M shares | −1.90 ppfrom 10.40% | Feb 14, 20255 filings | Feb 17, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 5.80%6.58M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
19 Schedule 13D and 13G filings on Dyne Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20266:04 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Mar 6, 202612:57 PM ET | T. Rowe Price Investment Management, Inc. | 13G/A | 16.20%26.6M shares | +5.50 ppfrom 10.70% | Feb 28, 2026 | SEC |
| Feb 17, 20264:34 PM ET | Janus Henderson Group PLC | 13G/A | 8.50%13.9M shares | −1.90 ppfrom 10.40% | Dec 31, 2025 | SEC |
| Jan 8, 202612:15 PM ET | T. Rowe Price Investment Management, Inc. | 13G | 10.70%17.5M shares | New | Dec 31, 2025 | SEC |
| Nov 14, 20254:14 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 0.00%0 shares | −8.50 ppfrom 8.50%Below 5% | Sep 30, 2025 | SEC |
| Nov 14, 202511:58 AM ET | Janus Henderson Group PLC | 13G/A | 10.40%14.7M shares | +0.30 ppfrom 10.10% | Sep 30, 2025 | SEC |
| Nov 13, 20254:23 PM ET | Atlas Venture Fund XI, L.P.and 8 others | 13G/A | 4.00%5.71M shares | –Below 5% | Sep 30, 2025 | SEC |
| Aug 7, 202510:34 AM ET | Janus Henderson Group PLC | 13G/A | 10.10%14.4M shares | +0.90 ppfrom 9.20% | Jul 31, 2025 | SEC |
| May 15, 20254:56 PM ET | Ra Capital Management, L.P.and 3 others | 13G/A | 8.50%9.71M shares | – | Mar 31, 2025 | SEC |
| May 15, 20253:54 PM ET | Point72 Asset Management, L.P.and 2 others | 13G/A | 1.50%1.67M shares | −3.60 ppfrom 5.10%Below 5% | Mar 31, 2025 | SEC |
| May 15, 20258:46 AM ET | Forbion Capital Fund IV Cooperatief U.A.and 4 others | 13G/A | 4.80%5.40M shares | –Below 5% | Mar 31, 2025 | SEC |
| May 15, 20258:17 AM ET | RTW Investments, LPand 1 other | 13G/A | 1.50%1.69M shares | −3.60 ppfrom 5.10%Below 5% | Mar 31, 2025 | SEC |
| May 14, 202512:16 PM ET | Janus Henderson Group PLC | 13G/A | 9.20%10.4M shares | +1.90 ppfrom 7.30% | Mar 31, 2025 | SEC |
| May 12, 202510:32 AM ET | FMR LLCand 1 other | 13G/A | 4.60%5.20M shares | −3.30 ppfrom 7.90%Below 5% | Mar 31, 2025 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 5.80%6.58M shares | – | Mar 31, 2025 | SEC |
| Feb 14, 202512:22 PM ET | Janus Henderson Group PLC | 13G/A | 7.30%7.38M shares | – | Dec 31, 2024 | SEC |
| Feb 14, 20259:00 AM ET | RTW Investments, LPand 1 other | 13G/A | 5.10%5.22M shares | – | Dec 31, 2024 | SEC |
| Feb 12, 20259:28 AM ET | FMR LLCand 1 other | 13G/A | 7.90%8.00M shares | – | Dec 31, 2024 | SEC |
| Feb 3, 20255:07 PM ET | Point72 Asset Management, L.P.and 2 others | 13G | 5.10%5.20M shares | New | Jan 31, 2025 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Dyne Therapeutics, Inc. shares.
No Form 144 notices for Dyne Therapeutics, Inc. are on file.